Alector ALEC
Alector Q1 FY24: revenue $15.9M; diluted EPS −$0.38
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-24-055682
- Document
- 10-Q
- Exhibit 10.1
- Material contract
- Exhibit 10.2
- Material contract
Key figures from this report
These are the numbers Alector reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$15.9MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income−$36.1MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS−$0.38No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$72.6MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$61.3MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.
- Protalix BioTherapeutics PLX public float $113M, Jun 30, 2025
- Fate Therapeutics FATE public float $113M, Jun 30, 2025
- Caribou Biosciences CRBU public float $113M, Jun 30, 2025
- Protara Therapeutics PRTO public float $112M, Jun 30, 2025
- TuHURA Biosciences HURA public float $111M, Jun 30, 2025